Home Cart Sign in  
Chemical Structure| 191732-72-6 Chemical Structure| 191732-72-6
Chemical Structure| 191732-72-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lenalidomide, a analog of thalidomide, is TNF-α secretion inhibitor with IC50 of 13 nM.

Synonyms: CC-5013

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Rathje, Oliver H. ; Perryman, Lara ; Payne, Richard J. ; Hamprecht, Dieter W. ;

Abstract: Mixed Lineage Kinase domain-Like pseudokinase (MLKL) is implicated in a broad range of diseases due to its role as the ultimate effector of necroptosis and has therefore emerged as an attractive drug target. Here, we describe the development of PROteolysis TArgeting Chimeras (PROTACs) as a novel approach to knock down MLKL through chem. means. A series of candidate degraders were synthesized from a high-affinity pyrazole carboxamide-based MLKL ligand leading to the identification of a PROTAC mol. that effectively degraded MLKL and completely abrogated cell death in a TSZ model of necroptosis. By leveraging the innate ability of these PROTACs to degrade MLKL in a dose-dependent manner, the quant. relationship between MLKL levels and necroptosis was interrogated. This work demonstrates the feasibility of targeting MLKL using a PROTAC approach and provides a powerful tool to further our understanding of the role of MLKL within the necroptotic pathway.

Alternative Products

Product Details of Lenalidomide

CAS No. :191732-72-6
Formula : C13H13N3O3
M.W : 259.26
SMILES Code : C1=CC=C(C3=C1C(N(C2C(NC(=O)CC2)=O)C3)=O)N
Synonyms :
CC-5013
MDL No. :MFCD07772307
InChI Key :GOTYRUGSSMKFNF-UHFFFAOYSA-N
Pubchem ID :216326

Safety of Lenalidomide

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H360
Precautionary Statements:P501-P202-P201-P280-P308+P313-P405

Application In Synthesis of Lenalidomide

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 191732-72-6 ]

[ 191732-72-6 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 51951-05-4 ]
  • [ 191732-72-6 ]
  • C21H27N3O8 [ No CAS ]
YieldReaction ConditionsOperation in experiment
60% Weigh 2.08g compound 63 (10mmol, 1eq.), add 100mL THF to dissolve, add 3.87g DIPEA (30mmol, 3eq), stir at room temperature for 10min, add 5.70g HATU (15mmol, 1.5eq.), stir at 40C for 30min, add 3.10 g of compound 6 (12 mmol, 1.2 eq.), reacted at 40C for 5 h, cooled to room temperature after the reaction was completed, and rotary-evaporated under reduced pressure to obtain the crude product, separated by silica gel column chromatography (DCM:MeOH=3:1), dried Dried compound 11 white powder 2.56g, yield 60%;
  • 2
  • [ 51951-05-4 ]
  • [ 191732-72-6 ]
  • C47H51ClN12O10S [ No CAS ]
 

Historical Records

Categories